avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2020-10-1-57-60avk-1000Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLEВыбор и классификация лекарственных препаратов при коморбидных заболеванияхSelection of medications in comorbidityБеляловФ. И.BelialovF. I.

Фарид Исмагильевич Белялов

Иркутск

Farid I. Belyalov

Irkutsk

fbelyalov@mail.ruГБОУ ДПО «Иркутская государственная медицинская академия последипломного образования» Минздрава РоссииРоссияIrkutsk State Medical Academy of Postgraduate EducationRussian Federation2020310120201015760Copyright © Белялов Ф.И., 20202020Белялов Ф.И.Belialov F.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/1000

В статье обсуждается классификация, ранжирующая влияние медикаментозных препаратов на коморбидные заболевания и состояния на пять классов с хорошим, возможным, нейтральным, нежелательным и негативным влиянием. Для удобного использования предложено дополнить классификацию буквенными обозначениями (А, В, С, D, Х). Классификация позволяет включить другие специализированные классификации медикаментов (например, разработанные для лечения беременных или пациентов старческого возраста), и призвана помочь практикующим врачам принимать оптимальные клинические решения с учетом принципов персонализированного подхода.

New classification divides medications on five classes by influence on comorbid diseases and conditions and rates drug’s effects as favourable (A), possible (B), neutral (C), undesirable (D), and unfavourable (X). Class A includes drugs used in treatment of comorbid disease, class B embraced drugs with positive influence, class C includes drugs without significant influence or contradictory influence, class D consist of drugs with possible nonsevere adverse effects, and class X includes drugs with severe adverse effects. The more universal drug classification according to influence on comorbid diseases can include and unite other classifications. Classification may help unify marks of positive and negative influences drugs on comorbidity and help practitioners in selection of effective and safe treatment.

коморбидностьклассификация медикаментовcomorbiditytreatmentclassification of medicinesReferencesБелялов Ф.И. Лечение болезней в условиях коморбидности. 11-е изд. Москва: ГЭОТАР-Медиа. 2019; 512 с. ISBN 978-59704 5073-4Belialov F. Treatment of diseases in comorbidity. 11th ed. M: GEOTAR-media. 2019; 512 p. ISBN 978-5-9704-5073-4 [In Russian].Pazan F., Weiss C., Wehling M. et al. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018; 35(1):61-71. doi: 10.1007/s40266-017-0514-2.Pazan F., Weiss C., Wehling M. et al. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018; 35(1):61-71. doi: 10.1007/s40266-017-0514-2.Laursen P., Holmvang L., Lønborg J. et al. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study. American Heart Journal. 2018; 204:128-38. doi: 10.1016/j.ahj.2018.05.018.Laursen P., Holmvang L., Lønborg J. et al. Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study. American Heart Journal. 2018; 204:128-38. doi: 10.1016/j.ahj.2018.05.018.Fanaroff A.C., Califf R.M., Windecker S. et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 20082018. JAMA. 2019; 321(11):1069–80. doi: 10.1001/jama.2019.1122.Fanaroff A.C., Califf R.M., Windecker S. et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 20082018. JAMA. 2019; 321(11):1069–80. doi: 10.1001/jama.2019.1122.Jepsen P. Comorbidity in cirrhosis. World Journal of Gastroe logy. 2014; 20(23):7223-30. doi: 10.3748/wjg.v20.i23.7223Jepsen P. Comorbidity in cirrhosis. World Journal of Gastroe logy. 2014; 20(23):7223-30. doi: 10.3748/wjg.v20.i23.7223Nardelli S., Pentassuglio I., Pasquale C. et al. Depression, anxiety and alexithymia symptoms are major determinants of health-related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis. 2013; 28(2):239-43. doi: 10.1007/s11011-012-9364-0.Nardelli S., Pentassuglio I., Pasquale C. et al. Depression, anxiety and alexithymia symptoms are major determinants of health-related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis. 2013; 28(2):239-43. doi: 10.1007/s11011-012-9364-0.Annema C., Drent G., Roodbol P.F. et al. Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up: A Prospective Cohort Study. Psychosomatic Medicine. 2018; 80(2):174-83. doi: 10.1097/PSY.0000000000000539Annema C., Drent G., Roodbol P.F. et al. Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up: A Prospective Cohort Study. Psychosomatic Medicine. 2018; 80(2):174-83. doi: 10.1097/PSY.0000000000000539Ratib S., Fleming K.M., Crooks C.J. et al. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol. 2015; 110(8):1149-58. doi: 10.1038/ajg.2015.191.Ratib S., Fleming K.M., Crooks C.J. et al. Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study. Am J Gastroenterol. 2015; 110(8):1149-58. doi: 10.1038/ajg.2015.191.Leithead J.A., Rajoriya N., Tehami N. et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015; 64:1111–9. doi: 10.1136/gutjnl-2013-306502Leithead J.A., Rajoriya N., Tehami N. et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015; 64:1111–9. doi: 10.1136/gutjnl-2013-306502Thiele M., Albillos A., Abazi R. et al. Non-selective beta-blockers may reduce risk of hepatocel-lular carcinoma: a metaanalysis of randomized trials. Liver Int. 2015; 35(8):2009–16. doi: 10.1111/liv.12782Thiele M., Albillos A., Abazi R. et al. Non-selective beta-blockers may reduce risk of hepatocel-lular carcinoma: a metaanalysis of randomized trials. Liver Int. 2015; 35(8):2009–16. doi: 10.1111/liv.12782Shi K.Q., Liu W.Y., Pan Z.Z. et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. Eur J Clin Invest. 2013; 43(8): 844-54. doi: 10.1111/eci.12115.Shi K.Q., Liu W.Y., Pan Z.Z. et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. Eur J Clin Invest. 2013; 43(8): 844-54. doi: 10.1111/eci.12115.Kim R.G., Loomba R., Prokop L.J., Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017; 15(10): 1521-30. doi: 10.1016/j.cgh.2017.04.039Kim R.G., Loomba R., Prokop L.J., Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017; 15(10): 1521-30. doi: 10.1016/j.cgh.2017.04.039Kamal S., Khan M.A., Seth A. et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017; 112(10):1495-1505. doi: 10.1038/ajg.2017.170Kamal S., Khan M.A., Seth A. et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017; 112(10):1495-1505. doi: 10.1038/ajg.2017.170Wright A.P., Adusumalli S.., Corey KE. Statin therapy in patients with cirrhosis. Frontline Gastroenterology. 2015; 6(4):255-261. doi: 10.1136/flgastro-2014-100500Wright A.P., Adusumalli S.., Corey KE. Statin therapy in patients with cirrhosis. Frontline Gastroenterology. 2015; 6(4):255-261. doi: 10.1136/flgastro-2014-100500Singh S., Singh P.P., Singh A.G. et al. Statins Are Associated with a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. Gastroenterology. 2013; 144[2]: 323-332. doi: 10.1053/j.gastro.2012.10.005Singh S., Singh P.P., Singh A.G. et al. Statins Are Associated with a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. Gastroenterology. 2013; 144[2]: 323-332. doi: 10.1053/j.gastro.2012.10.005Garcia-Tsao G., Abraldes J.G., Berzigotti A. et al. Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017; 65:310-35. doi: 10.1002/hep.28906.Garcia-Tsao G., Abraldes J.G., Berzigotti A. et al. Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis, and Management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017; 65:310-35. doi: 10.1002/hep.28906.Kubitza D., Roth A., Becka M. et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76(1):89-98. doi: 10.1111/bcp.12054Kubitza D., Roth A., Becka M. et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76(1):89-98. doi: 10.1111/bcp.12054Connolly S.J., Eikelboom J.W., Bosch J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018; 391(10117):205-18. doi: 10.1016/S01406736(17)32458-3.Connolly S.J., Eikelboom J.W., Bosch J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018; 391(10117):205-18. doi: 10.1016/S01406736(17)32458-3.Pudil R., Pelouch R., Praus R. et al. Heart failure in patients with liver cirrhosis. Heart Failure. 2013; 4: e391-6. DOI: 10.1016/j.crvasa.2013.06.002Pudil R., Pelouch R., Praus R. et al. Heart failure in patients with liver cirrhosis. Heart Failure. 2013; 4: e391-6. DOI: 10.1016/j.crvasa.2013.06.002Dimitriadis G., Papadopoulos V., Mimidis K. Eple reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatology International. 2011; 5(2):738-9. doi: 10.1007/s12072-010-9235-x.Dimitriadis G., Papadopoulos V., Mimidis K. Eple reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatology International. 2011; 5(2):738-9. doi: 10.1007/s12072-010-9235-x.Tandon P., Abraldes J.G., Berzigotti A. et al. Renin-angiotensinaldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010; 53(2):273-82. doi: 10.1016/j.jhep.2010.03.013.Tandon P., Abraldes J.G., Berzigotti A. et al. Renin-angiotensinaldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010; 53(2):273-82. doi: 10.1016/j.jhep.2010.03.013.Kim G., Kim J., Lim Y.L. et al. Renin-angiotensin system in and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016; 10(5):819-28. doi: 10.1007/s12072-016-9705-x.Kim G., Kim J., Lim Y.L. et al. Renin-angiotensin system in and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016; 10(5):819-28. doi: 10.1007/s12072-016-9705-x.Zhu Q., Li N., Li F. et al. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J Renin Angiotensin Aldosterone Syst. 2016; 17(1):1470320316628717. doi: 10.1177/1470320316628717.Zhu Q., Li N., Li F. et al. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J Renin Angiotensin Aldosterone Syst. 2016; 17(1):1470320316628717. doi: 10.1177/1470320316628717.

The authors declare that there are no conflicts of interest present.